RxDoctor Payments Data

Evan Guthrie, MD

Family Medicine · Harwich, MANPI 1750558474

Payments from drug & device makers

$351in general payments, 2019–2025

Across 12 payments — averaging $29.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$125
  • AbbVie$84
  • Novartis$48
  • Novo Nordisk$42
  • Abbott$19
  • Bayer$17
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$351100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK1$125
AbbVie(2 entities)3$84
Novartis3$48
Novo Nordisk2$42
Abbott1$19
Bayer1$17
RGH Enterprises LLC1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$351 in reported general payments places this provider in the 70th percentile of 1,049 family medicine providers in Massachusetts.

See all family medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$70,435
Medicare patients
204
Services billed
663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin38$52,900
EliquisApixaban32$39,734
TrulicityDulaglutide26$33,196
Breo ElliptaFluticasone/Vilanterol13$5,937
Varenicline Tartrate12$3,914
Atorvastatin Calcium170$1,455
Lisinopril154$1,343
Rosuvastatin Calcium93$1,292
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,222
Tamsulosin Hcl46$1,178
Levothyroxine Sodium97$1,130
Losartan Potassium105$934
Albuterol Sulfate HfaAlbuterol Sulfate27$828
Amlodipine Besylate111$729
Pregabalin11$724

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta$125$5,93713 claims
AbbVieSynthroid$84$16412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,049 family medicine providers in Massachusetts.

Other family medicine in Harwich

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →